Delivery Order SPE2DB24D2018-SPE2DB25FWWE2
- Not listed
- The Defense Logistics Agency awarded a $29,409.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Erleada 240 mg tablets in quantities of 30 units. The contract, which is not set-aside, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 9, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) with a firm fixed price structure. The delivery order is set to be completed by September 16, 2025, and represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office division located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $7,558.78 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Erleada 60 mg tablets (120 count). This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) valued at $7,558.78 under a firm fixed-price contract. The award, issued on August 11, 2025, with completion scheduled for September 2, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location,...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120 count) on August 19, 2025, with a completion date of September 10, 2025. This firm fixed-price contract is being performed at the contractor's Conshohocken, Pennsylvania location and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for Erleada 60 mg tablets (120 count) on September 2, 2025, with an ultimate completion date of September 23, 2025. This firm fixed price delivery order represents a non-competitive, non-set-aside award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $37,793.90 for 120-count supplies of Erleada 60 mg tablets, with an ultimate completion date of October 8, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under a larger indefinite delivery vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Erleada 240 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $7,352.49 and utilizes firm fixed price terms, with an ultimate completion date of October 3, 2025. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) under a firm fixed-price contract with an ultimate completion date of October 8, 2025. This competitively awarded, non-set-aside delivery order will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a routine pharmaceutical supply transaction supporting federal medical procurement needs. This...
- The Defense Logistics Agency awarded a delivery order valued at $14,704.98 to AmerisourceBergen Drug Corp for the supply of Erleada 240 mg tablets (30-count units) with a firm fixed price structure. This delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWE2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets in a quantity of 120 units, with a ceiling value of $7,558.78. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on August 11, 2025, with an ultimate completion date of September 2, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio with DLA encompasses a wide range of pharmaceutical products and medical supplies across multiple therapeutic domains. Erleada, an androgen receptor inhibitor used in oncology treatment, represents one of the specialized brand-name medications the company supplies through its prime vendor relationship. The delivery order structure and firm fixed pricing reflect standard federal procurement practices for pharmaceutical commodities, enabling the DLA to efficiently source medical supplies through an established contractor relationship that demonstrates proven capability to meet federal healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/11/25 |